GlassScriptPhysician profile
Amber D Lamus
NPI 1184084568
$1,171.49
in general payments reported to CMS, 2019-2025
10 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.44 · 2022: $54.05 · 2023: $315 · 2024: $213 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $389.43 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $229.20 | 2025 | |
| Neurocrine Biosciences, INC. | $201.94 | 2023-2025 | Ingrezza |
| Indivior INC. | $107.37 | 2023-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.37 | 2024-2025 | Caplyta |
| Bioxcel Therapeutics, INC. | $44.84 | 2023 | Igalmi |
| Axsome Therapeutics, INC. | $30.72 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $30.47 | 2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $29.69 | 2025 | Uzedy |
| Lundbeck LLC | $19.46 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Lamus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.